Cancer Medicines to Get Cheaper From 9 November: NPPA's 30% Trade Margin Cap on 137 Drugs, Explained
The National Pharmaceutical Pricing Authority has capped trade margins on 137 anti-cancer drugs at 30%, with revised prices due from 9 November 2026. The government says retail prices could fall by up to 70%. Here is what a trade margin cap is, which medicines are covered, how the new MRP is worked out, and what patients should do.
Cancer treatment in India is about to get cheaper for many families. The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% on 137 anti-cancer drugs, and the revised prices take effect from 9 November 2026. The government says retail prices of some of these medicines could fall by as much as 70%.
The 60-second version
- What: a 30% cap on trade margins for 137 non-scheduled anti-cancer drugs.
- Who ordered it: the NPPA, under the Department of Pharmaceuticals.
- Order date: 17 October 2026.
- New prices from: 9 November 2026.
- Expected impact: retail prices down by up to 70%, per the government.
- Also covered: patented cancer drugs and combination products.
- Legal basis: Paragraph 19 of the Drugs (Prices Control) Order, 2013.
What is a trade margin, and why cap it?
When a drug company sells a medicine, it first sells to a stockist or distributor at one price. The patient then pays the MRP printed on the pack. The difference between the two is the trade margin, which is split between distributors, wholesalers and the chemist.
For many cancer drugs that gap has been very wide. The government cited the "wide disparity between the procurement price and the Maximum Retail Price" as the reason for the order. Reports citing pharmaceutical market data put the average trade mark-up on non-scheduled anti-cancer drugs at about 170%, and up to 700% in some cases.
A trade margin cap does not tell companies what to charge their distributors. It limits how far above that supply price the MRP can be set.
How the new MRP is worked out
According to reports on the order:
- Start with the price to stockist or distributor, generally the price for March 2026.
- Allow a trade margin of up to 30%.
- Add GST.
Reports illustrate it with a simple example: a medicine sold to the stockist at Rs 70 can carry a maximum MRP of about Rs 100 before GST. Brands priced above the new ceiling must cut their MRP. Brands already below it must keep their existing MRP and cannot raise it to the cap.
Which medicines are covered?
The cap applies to non-scheduled formulations containing any of the 137 listed drugs, whether used alone or in combination, irrespective of dosage strength, dosage form or route of administration. It also covers patented medicines.
Drugs named in reports include:
| Drug | Commonly used for |
|---|---|
| Pembrolizumab | Immunotherapy used across many cancer types |
| Durvalumab | Immunotherapy, including lung cancer |
| Osimertinib | A targeted therapy for certain lung cancers |
| Denosumab | Breast and prostate cancer (bone-related use) |
| Pegfilgrastim | Preventing low white blood cell counts during chemotherapy |
| Bevacizumab | Colon, ovarian and cervical cancers |
Reports say the list includes immunotherapy drugs used for more than 20 types of cancer. The full list is in the NPPA order.
What companies have to do
- Send revised price lists to dealers and retailers within seven days.
- Put price information on their websites.
- Report prices to stockists and MRPs on the NPPA's Integrated Pharmaceutical Database Management System (IPDMS).
- Keep production and supply at current levels. Cutting average monthly production needs NPPA permission, and stopping production or imports needs at least six months' notice.
The last point matters: price caps sometimes raise fears of shortages, and the order tries to head that off.
Has this worked before?
Yes. In 2019, a pilot capped trade margins on 42 non-scheduled anti-cancer drugs at 30%. According to the government, the MRPs of 526 brands were then reduced by up to 90%. The new order extends the same approach to a much longer list, including newer and patented therapies.
What patients and families should do
- Do not stockpile now. Prices are due to fall from 9 November.
- Check the MRP on the pack from that date. Stock already with chemists must also be sold at the revised price once it applies.
- Ask your chemist or hospital pharmacy whether your specific brand has been revised. Not every brand will fall by the same amount, and some will not change at all if they were already below the cap.
- Report overcharging to the NPPA, which runs a grievance mechanism for medicine prices.
- Keep checking insurance and government schemes. Lower MRPs can stretch health cover and schemes such as Ayushman Bharat further, but the cap does not change what is covered.
The bottom line
The 30% trade margin cap targets the gap between what drug companies charge distributors and what patients pay at the counter. For families paying for months of cancer treatment out of pocket, savings of tens of thousands of rupees are possible on some therapies. How much any one patient saves will depend on the brand, and the real test will be whether the lower prices show up at chemists from 9 November.
Sources: Ministry statement and NPPA order as reported by The Statesman, Deccan Herald, Upstox and NewsBytes (17 to 19 October 2026). Figures on expected price cuts are government estimates.
Frequently asked questions
›What has the government done on cancer drug prices?
The National Pharmaceutical Pricing Authority (NPPA), in an order dated 17 October 2026, capped trade margins at 30% for 137 non-scheduled anti-cancer drugs. Revised prices take effect from 9 November 2026.
›How much cheaper will cancer medicines become?
The government has said retail prices could fall by up to 70%, depending on how much each brand currently marks up its price. Medicines that already sell below the new ceiling will not change, so the cut will vary from brand to brand.
›Which medicines are covered?
Formulations containing any of the 137 listed drugs, alone or in combination, in any strength or form. Reported examples include pembrolizumab, durvalumab, osimertinib, denosumab, pegfilgrastim and bevacizumab. Patented drugs are also covered.
›What is a trade margin?
It is the gap between the price at which a company sells a medicine to its stockist or distributor and the MRP the patient pays. The money in between is shared by distributors, wholesalers and chemists. Capping it limits how far above the supply price the MRP can be set.
›Has this been done before?
Yes. In 2019 a pilot capped trade margins on 42 non-scheduled anti-cancer drugs at 30%. According to the government, the MRPs of 526 brands were later reduced by up to 90%.